CGON Stock News & Analysis | Latest Updates

CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences

(NASDAQ:CGON) IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, are scheduled to participate in fireside chat presentations at the following investor conferences:

CGON News

CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences

Morgan Stanley Maintains Overweight on CG Oncology, Lowers Price Target to $52

CG Oncology Q1 EPS $(0.45) Misses $(0.41) Estimate, Sales $52.00K Miss $212.75K Estimate

JP Morgan Initiates Coverage On CG Oncology with Overweight Rating, Announces Price Target of $41

RBC Capital Maintains Outperform on CG Oncology, Raises Price Target to $68

Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook

CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why

Cantor Fitzgerald Reiterates Overweight on CG Oncology, Maintains $75 Price Target

Dow Jumps Over 150 Points; Domino's Pizza Posts Upbeat Earnings

HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target

Reported Saturday, CG Oncology Reports Durability In BOND-003 Cohort C And Encouraging Early Results In Cohort P For Cretostimogene Grenadenorepvec

This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Scotiabank Initiates Coverage On CG Oncology with Sector Perform Rating, Announces Price Target of $23

HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target

CG Oncology Reports Q4 EPS Of ($0.46) Compared With $(4.36) YoY; Exits Quarter With Cash & Equivalents Worth $257.068M

Expert Outlook: CG Oncology Through The Eyes Of 4 Analysts

HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target

3 Analysts Assess CG Oncology: What You Need To Know

Morgan Stanley Assumes CG Oncology at Overweight, Maintains Price Target of $55

ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug

HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target

HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target

CG Oncology To Present At Society of Urologic Oncology (SUO) 25th Annual Meeting Dec. 4-6